Johannes Ramaekers

Professor of Psychopharmacology

Data updated

Papers

65 publications

Trials

0 clinical trials

Research Footprint

Johannes Ramaekers appears in 65 tracked papers (2005–2026), most studied alongside Psilocybin, MDMA and Ayahuasca, across Healthy Volunteers, Depressive Disorders and Anxiety Disorders.

Most-cited paper: Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin (258 citations).

Frequent co-authors: Nathalie Mason, Kim Kuypers and Jan Reckweg.

Background & Research

Johannes Ramaekers is a Professor of Psychopharmacology and Behavioral Toxicology at Maastricht University. His research focuses on how various drugs, including psychedelics and cannabis, affect cognitive functions such as memory, attention, and creativity. He is a prominent figure in behavioral toxicology and has published extensively on the therapeutic and performance-related impacts of psychoactive compounds.

Key Impact

Leading expert in behavioral toxicology and the impact of psychoactive substances on human performance and cognition.

65

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

73 collaborators· click a node to visit their profile

Full network →

Compounds

PsilocybinMDMAAyahuascaLSD5-MeO-DMTPlaceboDMTMescaline2C-X

Topics

Healthy VolunteersDepressive DisordersAnxiety DisordersNeuroimaging & Brain MeasuresSubstance Use Disorders (SUD)MicrodosingCreativityChronic PainSet & SettingTreatment-Resistant Depression (TRD)Safety & Risk ManagementInterpersonal Functioning & Social ConnectednessHeadache Disorders (Cluster & Migraine)Immunology & InflammationPTSDMedicinal Chemistry & Drug DevelopmentPersonality & Trait FactorsEquity and EthicsNeurocognitive DisordersPublic Health, Prevention & Behaviour ChangeSchizophreniaPalliative & End-of-Life DistressMajor Depressive Disorder (MDD)Alcohol Use Disorder (AUD)FibromyalgiaObsessive-Compulsive Disorder (OCD)

Top Collaborators

Affiliations

Institutions, companies, and organisations Johannes Ramaekers is associated with.

Maastricht University

academic
Faculty / StaffCurrent

Professor of Psychopharmacology

While Maastricht University may not have a single dedicated psychedelic research group, various researchers at the university are investigating the effects of psychedelics. Early research exploring psychedelics at Maastricht focused on the dangers of MDMA. Now, research into the effects of microdosing is being led by Dr Kim Kuypers. Other research ongoing at the university is investigating cannabis as well as novel psychoactive substances (NPS). Maastricht is collaborating on research with the Beckley Foundation as well as Silo Pharma.

View stakeholder →

GH Research

Public Biotech
Advisor

GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Dublin, Ireland, developing novel mebufotenin (5-MeO-DMT) therapeutics for treatment-resistant depression, bipolar II disorder, and postpartum depression. Its lead asset GH001 — an inhaled mebufotenin formulation — met the primary endpoint of its Phase 2b TRD trial in February 2025 with striking results: -15.5 point MADRS reduction vs placebo (p<0.0001) and 57.7% remission vs 0%. With a single-day dosing paradigm requiring no structured psychotherapy, GH001 is positioned as a differentiated asset; Phase 3 global initiation is planned for 2026 following FDA clinical hold lift. GH002 (IV mebufotenin) completed Phase 1 in healthy volunteers.

View stakeholder →